Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control
Event:
ESC Preventive Cardiology 2021
Topic:
Health Economics
Session:
Rapid fire abstracts - Secondary Prevention and Rehabilitation